June 23, 2022

Blue Fin Group Releases Explanatory Video on Impacts and Future of Public Health Service 340B Program

New York, June 23, 2022 – Blue Fin Group, a full-service management consulting firm to the pharmaceutical industry, today announced the availability of an in-depth video by Principal Consultant Timothy Paine that explores the Public Health Service 340B program, its evolution over 30 years, and what is expected in the coming decade. Created in 1992, the 340B program requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for many uninsured and low-income patients. In the video, Paine explores the massive expansion of hospital eligibility and 340B dollars, the growth of more expensive specialty brands, the allowance and expansion of contract pharmacies, and ongoing controversies. Looking ahead to 2032, he examines the impact on and implications for patients, prescribers, payers, pharmacies, and the physical channel or flow of medications. 

About Timothy Paine
With more than three decades of experience in the life sciences industry, Paine has significant experience taking pharmaceutical and biotech products to market. His experience spans commercial development from clinical trial through loss of exclusivity. Paine has worked across a wide range of therapeutic areas and is deeply familiar with cell and gene therapies, orphan rare diseases, and an array of specialty areas. Prior to joining Blue Fin Group, he was Vice President, Pharmaceutical Strategy and Relations, for Fairview Pharmacy Services, part of the M Health Fairview Health System. A full biography is available here.

About Blue Fin Group, an IntegriChain Company
Blue Fin Group develops strategies to optimize patient access, commercialization, and gross-to-net to support life sciences manufacturers throughout the product life cycle. Blue Fin Group is a full-service management consulting firm delivering research, strategy, and implementation to help manufacturers align all the elements of marketing, market access, field sales, pharmacy and distribution, and patient services as a seamless commercial strategy that helps optimize patient outcomes. Blue Fin Group has served more than 300 manufacturers–primarily those commercializing their first asset or large global firms with products that span cell and gene therapies, orphan/rare, specialty, primary care, vaccines, biosimilars, and generics. For additional information, visit https://consultbfg.com/ or follow on Twitter and LinkedIn.

For Media Inquiries: Contact Cynthia Keveney at ckeveney@consultbfg.com